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Abstract (Word count 238) 
Aims:  Objective identification of patient risk profile in Oesophageal Cancer 
(OC) surgery is critical. This study aimed to evaluate to what extent 
cardiorespiratory fitness and select metabolic factors predict clinical outcome.  
Methods: Consecutive 186 patients were recruited (median age 69 yr. 160 
male, 138 neoadjuvant therapy). All underwent pre-operative cardiopulmonary 
exercise testing to determine peak oxygen uptake (?̇?O2Peak), anaerobic 
threshold (AT), and ventilatory equivalent for carbon dioxide (?̇?E/?̇?CO2). 
Cephalic venous blood was assayed for serum C-reactive protein (CRP), 
albumin, and full blood count. Primary outcome measures were Morbidity 
Severity Score (MSS), and Overall Survival (OS). 
Results: MSS (Clavien-Dindo >2) developed in 33 (17.7%) and was related 
to elevated CRP (AUC 0.69, p=0.001) and lower V ̇O2Peak (AUC 0.33, 
p=0.003). Dichotomisation of CRP (above 10mg/L) and V ̇O2Peak (below 
18.6mL/kg/min) yielded adjusted Odds Ratios (OR) for MSS CD>2, of 4.01 
(p=0.002) and 3.74 (p=0.002) respectively. OC recurrence occurred in 36 
(19.4%) and 69 (37.1%) patients died. On multivariable analysis; pTNM stage 
(Hazard Ratio (HR) 2.20, p=0.001), poor differentiation (HR 2.20, p=0.010), 
resection margin positivity (HR 2.33, p=0.021), and MSS (HR 4.56, p<0.001) 
were associated with OS.  
Conclusions: CRP and V ̇O2Peak are collective independent risk factors that 
can account for over half of OC survival variance.  
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Introduction 
Never before has there been such a variety of treatment modalities available, 
which in multimodal form can now cure as many as one-in-two oesophageal 
cancer (OC) patients.1 Oesophagectomy remains the primary therapeutic 
modality for radical and potentially curative treatment for patients with OC, but 
despite recent advances in anesthesiology and critical care it continues to 
carry significant inherent risk. Indeed, the 2018 UK National Oesophago-
Gastric Cancer Audit 2 reported post-operative morbidity and mortality of 50% 
and 1.6% respectively. Current approaches to risk prediction comprise: 
clinical judgement, objective scoring systems such as the Portsmouth 
Physiological and Operative Severity Score for the enUmeration of Mortality 
and Morbidity (P-POSSUM)3, Oesophagogastric POSSUM (O-POSSUM)4, 
American Society of Anesthesiologists (ASA) physical status, Charleston 
Comorbidity Index, serum biomarkers, measures of cardiac function5, and the 
shuttle walk tests6. Their effectiveness in predicting surgical morbidity is 
relatively weak and measures to improve a clinician’s ability to predict 
outcome are needed. Cardiopulmonary exercise testing (CPET) is a non-
invasive and dynamic procedure, which allows an individual’s 
cardiopulmonary fitness to be accurately measured. 7 CPET, in particular an 
anaerobic threshold <11 mL/kg/min, has been reported to predict post-
operative morbidity and mortality in patients undergoing major abdominal 
surgery,1,8–10 yet, although well established in cardiothoracic surgery11, its 
application in the OC setting is limited.10,12  
Cancer-related inflammation has been dubbed the seventh hallmark of 
cancer,13 and the systemic inflammatory response (SIR) is measured using 
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cellular white cell counts (neutrophils, lymphocytes and platelets), humoral [C-
reactive protein (CRP) and albumin] components. Derivative biomarkers 
(neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), 
neutrophil-platelet score (NPS), and the modified Glasgow Prognostic Score 
(mGPS) have also been reported to be associated with survival.14–16 Despite 
emerging evidence that the SIR is associated with post-operative morbidity in 
colorectal cancer17,18, confirmatory evidence in OC is thin.  
In light of the above, the present study examined to what extent select 
metrics of cardiorespiratory fitness and metabolic risk factors predict clinical 
outcome in OC patients scheduled for elective surgery. The hypothesis was 
that impaired cardiorespiratory fitness (CRF) and elevated CRP would predict 
patient morbidity and mortality. The primary outcome measures were post-
operative morbidity severity, Overall Survival (OS), and Disease-Free survival 
(DFS) 
 
Methods 
Governance 
Ethical approval was sought from the regional ethics committee, but a formal 
application was deemed unnecessary, because the study was considered to 
be a service evaluation of consecutively recruited patients, in whom consent 
had already been provided.  
 
Patients 
Selection/staging: In order to test the hypotheses proposed in this study, a 
single cohort of patients diagnosed with oesophageal adenocarcinoma, 
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between January 1, 2010 and August 31, 2018, was developed and included 
patients with radiological TNM stage I to III, deemed to have amenable to 
treatment with curative intent. All patients were managed by a 
multidisciplinary specialist team (MDT), with an interest in OC, and included 
clinical nurse specialists, gastroenterologists, surgeons, oncologists, 
radiologists, anaesthetists and pathologists.19 Management plans were 
individually tailored according to factors relating to both the patient and their 
disease. Patients were staged using computed tomography, endoscopic 
ultrasound, computed tomography positron emission tomography, and staging 
laparoscopy as appropriate. The South East Wales MDT treatment algorithms 
for OC have been described previously.20,21 The majority of these patients 
received 2 cycles of 80mg/m2 of Cisplatin and 1000mg/m2 of 5-FU for 4 days. 
A minority received 3 cycles of Epirubicin (50mg/m2), Cisplatin (60mg/m2) and 
5-Fu (200 mg/m2) or Capecitabine (625mg/m2; ECF/X). Definitive 
chemoradiotherapy was offered to patients with localized squamous cell 
carcinoma and patients with adenocarcinoma deemed unsuitable for surgery 
because of disease extent and/or medical co-morbidity.22,23  
 
Surgical intervention: The standard operative approach was subtotal Trans-
Thoracic Oesophagectomy (TTO) as described by Lewis and Tanner.24,25 
Trans-Hiatal Oesophagectomy (THO), as described by Orringer26, was used 
selectively in patients with adenocarcinoma of the lower third of the 
esophagus who had significant cardiorespiratory co-morbidity, clinical T1-3 N0 
disease. A modified extended D2 lymphadenectomy (preserving pancreas 
and spleen where possible) was performed and the operative approach was 
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open in 120 cases with 16 patients undergoing laparoscopic assisted surgery. 
 
Clinico-pathological Characteristics 
Tumours were staged using the seventh edition of the AJCC/UICC-TNM 
staging system. Pathological factors were recorded from pathology reports 
issued at the time of surgery using AJCC/UICC-TNM staging system (seventh 
edition), and included tumour differentiation, number of lymph nodes with and 
without metastasis, and margin status.  
Routine laboratory measurements of haemoglobin, whole white-cell count, 
neutrophil count, lymphocyte count, platelet counts, CRP, and Albumin on the 
day prior to surgery were recorded. Derivate measurements of systemic 
inflammation consisted of the NLR and PLR.14 The NLR and PLR were 
constructed by calculating the neutrophil to lymphocyte ratio and the platelet 
to lymphocyte ratio respectively.14,27  
 
CPET testing 
CPET followed American Thoracic Society/ American College of Chest 
Physicians recommendations.11 All patients performed a symptom limited 
CPET conducted on an electromagnetically braked cycle ergometer, and 
comprised 2 to 3min rest phase (to allow gas exchange variables to stabilise), 
3 min unloaded cycling, then a ramped incremental protocol until volitional 
termination, and 2 to 5min recovery period. Ventilation and gas exchange was 
measured with a Medgraphics UltimaTM metabolic cart (Medical Graphics, St 
Paul, Minnesota, USA) with BreezesuiteTM and Welch Allyn® (Welch Allyn, 
Inc., NY, USA) software as described previously.12  
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Heart rate, blood pressure, pulse oximetry, and 12-lead electrocardiogram 
were monitored throughout. The ramp gradient was set to 10 to 20 Watts 
based on the predicted V ̇O2Peak from the age, weight, height, and sex of the 
patient in order to produce an exercise test of between 8-12 minutes duration 
28. Prior to each test, the CPET equipment was calibrated against reference 
gases. The AT was determined using the V-slope method and confirmed by 
changes in ventilatory efficiency for oxygen (?̇?E/?̇?CO2) and end-tidal partial 
pressure values for oxygen (PETO2).28 The AT was validated independently by 
two experienced observers (IA and RD). V ̇O2Peak was the highest V ̇O2 
achieved during the final 30 seconds of the test. The ?̇?E/?̇?CO2 slope was 
measured at the AT. Test termination criteria included: request of patient, 
volitional fatigue, chest or leg pain, or electrocardiographic abnormalities 
determined by the consultant anesthetist. Multidisciplinary discussion and 
stratification of individual patient risk informed decisions regarding the 
planned post-operative level of care and invasive monitoring.  
 
Morbidity/mortality 
Operative morbidity was graded in accordance with the Clavien-Dindo 
Classification (CDC).29–31 Particular emphasis was placed on the incidence of 
morbidity of Clavien-Dindo grade >2, as this represented a complication 
requiring endoscopic, radiological or surgical intervention, in contrast with 
morbidity of lower grade requiring only pharmacological treatment. 
 
Patient follow-up 
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Patients were followed up at 3-monthly intervals for the first year and 6 
months thereafter. Investigations were undertaken sooner in the event that 
patients developed symptoms suggestive of recurrent disease. Surveillance 
was conducted for 5 years or until death, whichever was sooner.32 OS was 
calculated from time of diagnosis to the date of death. DFS was measured 
from the date of surgery until the date of recurrence or date of censoring. 
Causes of death were obtained from the Office for National Statistics via 
Cancer Network Information System Cymru (CaNISC). Recurrence patterns, 
which were characterised at the time of first diagnosis, were defined as loco-
regional, distant (metastatic), or both. The date of recurrence was taken as 
the date of the confirmatory investigation. 
 
Statistical Analysis 
Statistical analyses were performed using SPSS® (IBM® SPSS® Statistics 
v25.0.0.0, IBM Corporation, Armonk, New York, USA) with extension R. 
Grouped data, that was not normally distributed based on Shapiro Wilks-W 
test, were expressed as median (interquartile-range) and non-parametric 
methods used. Receiver-operator-characteristic (ROC) analyses were 
employed to assess the predictive value of continuous variables with primary 
outcome measures and thresholds dichotomized for major morbidity as 
described by Youden et al.33 For categorical variables, univariable and 
multivariable logistical regression analysis was used to identifying 
independent associations with major morbidity.  Patient demographics were 
analyzed between the treatment modalities by means of Chi-Square χ2 or 
Mann Whitney U tests. Disease-free survival for all patients was calculated by 
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measuring the interval from a landmark time of 6 months after diagnosis to the 
date of recurrence. This approach was adopted in previous randomized 
trials,34 to allow for the variable interval to surgery following diagnosis, 
depending on whether NeoAdjuvant Chemotherapy (NAC) was prescribed. As 
in these trials, events resulting in a failure to complete curative treatment, 
such as not proceeding to surgery, open and close laparotomy, palliative 
resection, in-hospital mortality and disease progression during NAC, were 
assumed to have occurred at this landmark time, to maintain the intention-to-
treat analysis. Overall survival was measured from the date of diagnosis. 
Cumulative survival was calculated according to the method of Kaplan and 
Meier; differences between groups were analyzed with the log rank test. 
Univariable analyses examining factors influencing survival were examined 
initially by the life table method of Kaplan and Meier, and those with 
associations found to be significant (p<0·100) were retained in a Cox 
proportional hazards model using backward conditional methodology to 
assess the prognostic value of individual variables.  
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Results 
In total, 186 patients were identified who underwent potentially curative 
oesophagectomy for cancer. Twenty-five patients (13.4%) were deemed 
inoperable because of local tumour invasion. Of the patients undergoing 
surgical resection, 72 (44.7%) underwent a TTO, and 89 (55.3%) a THO. The 
median age for patients undergoing surgery was 69 years (IQR 64-73), 160 
(86.0%) were male and 26 (14.0%) female. One hundred and thirty-eight 
(74.2%) patients underwent neoadjuvant chemotherapy. One hundred and 
one (54.3%) of patients developed a post-operative complication, with 33 
(17.7%) being classified as major according to a Clavien-Dindo score of >2. 
There were five (2.7%) perioperative deaths. During follow-up, 36 patients 
(19.4%) developed cancer recurrence and 69 patients (37.1%) died. Median 
follow-up of survivors was 27 (range 7-60) months. One hundred and four 
(55.9%) patients were followed up for at least 5 years or death. 
 
Relationship between markers of the systemic inflammatory response, 
physiological variables, and MSS 
The baseline and area-under-curve values for markers of the systemic 
inflammatory response and physiological variables can be found in table 1. 
There was no association between serum CRP and physiological parameters, 
with correlation values for anaerobic threshold (Spearman’s correlation 
coefficient (SCC) -0.080, p=0.286), V ̇O2Peak (SCC -0.090, p=0.224), and 
?̇?E/?̇?CO2 (SCC 0.093, p-0.210) were not statistically significant. Findings were 
similar for NLR and PLR (data not shown). Using a previously published 
dichotomization value of 10 mg/L14, 33 (17.7%) patients had a raised CRP. 
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There was no difference between the median measurements of V ̇O2Peak, AT 
or ?̇?E/?̇?CO2, in patients with normal or high CRP respectively. The median 
value for CRP was 3 mg/L (interquartile range (IQR) 1-7). CRP was strongly 
associated with MSS (AUC 0.69 (95% CI 0.60-0.79), p=0.001, figure 1a). The 
median value for V ̇O2Peak was 19.6 mL/kg/min (IQR 16.4-23.5) and anaerobic 
threshold (AT) was 11.5 mL/kg/min (IQR 10.1-13.7) (table 1). Using the 
Youden index, the optimum dichotomization threshold for V ̇O2Peak was 18.6 
mL/kg/min (figure 1b), and AT was 11.5 mL/kg/min with 43.5% and 48.9% of 
patients considered to have low measurements respectively. This gave 
sensitivity and specificity of 69.7% and 62.1% respectively for V ̇O2Peak, and 
69.7% and 53.4% respectively for AT. Total morbidity (CD>1) and operative 
mortality rates were 53.1% and 1.2% for low V ̇O2Peak and 60.2% and 2.3% for 
low AT respectively. 
To adjust for potential confounders, a binary logistical regression model 
was developed to include the clinical factors available to the MDT at the point 
of deciding on definitive treatment (table 2). On univariable binary logistical 
regression analysis, only CRP (p=0.022), V ̇O2Peak (p=0.001), and AT 
(p=0.069), were associated with major morbidity. On multivariable logistical 
regression analysis, CRP (odds ratio (OR) 4.01 (95% CI 1.66-9.66), p=0.002) 
and V ̇O2Peak (OR 3.74 (95% CI 1.62-8.65), p=0.002) were independently 
associated with major morbidity. A composite score was developed to 
determine if major morbidity could be predicted with greater accuracy. The 
Combined Inflammatory and Physiology Score (CIPS) ranged from zero to 
two. Patients with a normal CRP and V ̇O2Peak were given a score of zero 
(low), a score of one (intermediate) was given to patient if either the CRP was 
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high or V ̇O2Peak was low, and a score of two (high) was given to patients with 
both an elevated CRP and low V ̇O2Peak. This resulted in 88 (47.3%), 80 
(43.0%), and 18 (9.7%) patients being classified with CIPS of low, 
intermediate, and high respectively. The major morbidity rate was 9.1% (n=8), 
17.5% (n=14), and 61.1% (n=11) in the low, intermediate, and high CIPS 
cohorts respectively (p<0.001). A stepwise association between advancing 
CIPS and major morbidity was observed. Compared with the low CIPS cohort, 
OR was 2.12 (95% CI 0.84-5.36) for intermediate, and 15.71 (4.76-51.87, 
p<0.001) for high CIPS.  
 
Relationship between clinicopathological factors and OS  
The relationship between clinicopathological factors and OS can be found in 
table 3. The cumulative OS for CIPS and MMS can be found in figure 2. 
 
Relationship between clinicopathological factors and DFS  
The relationship between clinicopathological factors and DFS can be found in 
table 4. 
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Discussion 
The principal finding of this study was that metabolic measures of the 
Systemic Inflammatory Response (SIR) together with physiological measures 
of cardiorespiratory fitness (V ̇O2Peak), were independently associated with 
major complications after potentially curative oesophagectomy for cancer, 
supporting the primary hypothesis. Major operative morbidity was three-fold 
higher in patients with high CRP and poor CRF, with a sensitivity and 
specificity of 39.4% and 85.6% for CRP and 69.7% and 62.1% for V ̇O2Peak, 
respectively. Moreover, combining these parameters established a novel 
composite risk score (CIPS). Based on a CIPS of two, no fewer than 11 of 18 
patients (61.1%) developed major morbidity, compared with eight (9.1%) with 
a CIPS of zero. Similarly, patients with a CIPS of zero experienced five-year 
OS that was more than two-fold greater at 50%, compared with 18% in 
patients with a CIPS of two.   
Previous reports have contended that the SIR is closely associated 
with post-operative complications in colorectal cancer35. Richards et al, 
reported that CDC morbidity rates were 28% and 44% in patients with a 
modified Glasgow Prognostic Score of zero and two respectively. The 
pathophysiological cause for this association is unclear but likely relates to the 
underlying aetiology of the SIR, with aggressive tumour biology and individual 
patient CRF likely contributing factors. In the presence of cardiovascular 
disease, diabetes, poor diet, obesity, and smoking have all been reported to 
be associated with elevated CRP and poorer prognosis36. Moreover, 
modification of these lifestyle factors resulted in SIR resolution. Nevertheless, 
the data here did not show any correlation between raised CRP and 
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physiological factors, arguably supporting the concept that an activated SIR 
prior to surgery has a multifactorial aetiology. We have previously 
demonstrated that a low V ̇O2Peak is independently associated with major 
morbidity following oesophagectomy for OC, and measures to attenuate the 
SIR and poor CRF have the potential to reduce morbidity and prolong 
survival37. Unfortunately, data on lifestyle factors and anti-inflammatory use 
were not available for analysis and their associations with pre-operative 
inflammatory and physiological factors is worthy of further study. 
These findings raise the possibility of whether a focused programme of 
prehabilitation combined with measures to attenuate the SIR, may reduce 
peri-operative complications, and enhance survival. Barberan-Garcia et al 
reported a randomised control trial (RCT) of prehabilitation in elective major 
abdominal surgery38 and showed that prehabilitation reduced postoperative 
complications by 51%. Unfortunately, approximately 60% of patients 
undergoing oesophagectomy will develop post-operative morbidity, most 
related to compromised respiratory function39. Minnella et al, of Montreal, 
Canada, reported a randomised control trial of respiratory function prior to and 
following surgery40. Prehabilitation was associated with higher functional 
capacity before surgery (mean [SD] 6MWD change, 36.9 [51.4] vs. −22.8 
[52.5] m; p < .001), which was maintained into the post-operative period (15.4 
[65.6] vs. −81.8 [87.0] m; p < 0.001). Results, which are very promising for a 
patient cohort whose functional and oncological outcomes, are relatively poor. 
Based on the prevailing evidence, it appears that prehabilitation 
programmes including measures to attenuate the SIR are desirable if not 
urgently needed. What remains to be clarified is what optimum method of SIR 
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attenuation is most suited to cancer patients, carrying significant pre-existing 
morbidity, and facing complex major surgery. Moreover, will patients with a 
CIPS>0 derive the most benefit from these attenuation measures? Although it 
would seem reasonable to incorporate anti-inflammatory medication into a 
prehabilitation care package, emerging evidence suggests that this is not 
without risk. A meta-analysis of Non-steroidal anti-inflammatory use in 
colorectal surgery suggested an increased risk of anastomotic leak (OR 
1.96)41. A similar finding was also observed in patients undergoing 
oesophago-gastrectomy (OR 5.24)42. Yet these findings remain controversial, 
indeed McSorley et al reported that two doses of peri-operative 
dexamethasone, reduced the post-operative inflammatory response and 
complication rate in patients undergoing colectomy for cancer43. Therefore, it 
may be that patients with a CIPS>0, which accounted for 75% 0f all major 
morbidity in this study, will derive the most benefit from SIR attenutation. The 
main causes of major post-operative morbidity in patients undergoing 
oesophagectomy are related to sepsis, namely respiratory failure and 
anastomotic leak. Given that wound healing relies heavily on the inflammatory 
response, it may be prudent to omit NSAIDs and other anti-inflammatory 
medication from the prehabilitation bundle. The findings by Sattar and 
colleagues that lifestyle modification reversed the SIR also support this 
concept 36. It is possible that a proportion of patients with a SIR may not 
respond to prehabilitation, and therefore constitute a self-selecting cohort that 
may benefit from pharmacotherapy. Adequately powered studies to examine 
the effect of prehabilitation on SIR modulation are clearly needed to guide 
prehabilitation programme development.   
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 Validating these results in an appropriately powered independent 
cohort would help integrate this novel combined inflammation-physiological 
score into a modified OG cancer treatment pathway, but a number of 
potential inherent and hypothetical limitations, related to the methodology of 
the present study mean that the findings must be interpreted with caution. 
The patient cohort constituted a highly selected group (most had undergone 
a potentially curative R0 oesophagogastrectomy), and were not universally 
representative of patients diagnosed with oesophageal cancer.44 Moreover, 
clinical access to CPET remains limited, with the most recent literature 
reporting that only 32% of UK hospitals have ready access to this applied 
multidisciplinary physiological asset45. Data relating to blood loss and 
operation time was not collected for this study and therefore is not available 
for analysis. Nevertheless, it is unlikely that these are considerable 
confounders for SIR and physiology variables in predicting post-operative 
morbidity. CPET assessment was first introduced in 2010 and therefore the 
follow-up period is slightly immature, nevertheless, strong statistical signals 
are identified and CIPS is worthy of validation in an independent cohort. In 
contrast, the study has several strengths, benefiting from robust follow-up 
data - two thirds of patients followed up for at least 5 years or death - with 
accurate causes and dates of death obtained from the office of national 
statistics. A NHS laboratory using standardized techniques performed the 
serum measurements and reporting of pathology specimens, and therefore 
re-examination of these findings in another comparable OC patient cohort, 
should be eminently pragmatic. Moreover, the patients were recruited from a 
consecutive series of patients diagnosed with OC, from a single UK 
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geographical region, all treated by the same specialist MDT, using a 
standardized staging algorithm and team-based operative techniques, with 
international audited and published quality control.19  
In conclusion, CRP and V ̇O2Peak are important in the risk assessment of 
patients undergoing oesophagectomy for cancer. Combining these variables 
into a novel prognostic score improved the predictive accuracy further.  
Refining cardiopulmonary fitness by using a multimodal prehabilitation 
treatment bundle may also attenuate the SIR, potentially reducing post-
operative morbidity, improving quality of life, and long-term survival, without 
the need for anti-inflammatory medication.   
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Table 1. Association between markers of the systemic inflammatory response, physiological variables, and major morbidity 
 
Median (IQR) Low / Normal / High (n)* Area-Under-Curve  
(95% Confidence interval) 
 p-value 
Serum variables 
    
Haemoglobin 133 (120-142) 75 / 111 / 0 0.45 (0.34-0.55) 0.318 
White Cell Count 4.3 (5.2-7.8) 11 / 173 / 2 0.60 (0.49-0.72) 0.061 
Neutrophil Count 3.9 (3.0-5.1) 8 / 171 / 7 0.59 (0.48-0.70) 0.104 
Lymphocyte Count 1.6 (1.1-2.0) 27 / 153 / 6 0.54 (0.44-0.65) 0.426 
Platelet Count 241 (203-291) 5 / 175 / 6 0.51 (0.39-0.63) 0.877 
C-Reactive Protein 3.0 (1.0-7.0) 0 / 151 / 35 0.69 (0.60-0.79) 0.001 
Neutrophil-Lymphocyte Ratio 2.64 (1.88-3.71)  0.55 (0.44-0.65) 0.415 
Platelet-Lymphocyte Ratio 157 (124-223)  0.46 (0.35-0.57) 0.482 
     
CPEX variables     
Anaerobic threshold  11.5 (10.1-13.7)  0.40 (0.30-0.51) 0.082 
V ̇O2Peak  19.6 (16.4-23.5)  0.33 (0.23-0.43) 0.003 
?̇?E/?̇?CO2 30.0 (27.0-33.3)  0.63 (0.52-0.73) 0.024 
     
* Based on local thresholds  
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Table 2. Univariable and multivariable analysis of pre-operative factors associated with major morbidity 
 
Univariable 
Odds ratio (95% CI) 
 p-value Multivariable 
Odds ratio (95% CI) 
 p-value 
Age (Years) (<65 / 66-75 / >75) 1.29 (0.73-2.26) 0.386     
Gender (Female / Male) 1.29 (0.42-4.02) 0.658     
Differentiation (Well-moderate / Poor) 0.56 (0.26-1.22) 0.144   
 
cTNM (1 / 2 / 3 / 4) 0.844 (0.46-1.56) 0.590   
 
Neoadjuvant therapy (No / Yes) 0.62 (0.28 – 1.37) 0.239   
Surgical approach (THO / TTO) 1.11 (0.51-2.40) 0.792   
C-reactive Protein (Normal  / High) 2.85 (1.16 – 6.98) 0.022 4.01 (1.66-9.66) 0.002 
V ̇O2Peak (<18.6 / ≥18.6) 3.92 (1.76 – 8.73) 0.001 3.74 (1.62-8.65) 0.002 
Anaerobic Threshold (<11.5 / / ≥11.5) 2.06 (0.95-4.50) 0.069  0.735 
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Table 3. Univariable and multivariable analysis of factors associated with OS 
 
 
 
 
  Univariable 
HR (95% CI) 
  
p-value 
Multivariable 
HR (95% CI) 
  
p-value 
Age (<65 / 66-75 / >75 yr) 1.11 (0.78-1.58)) 0.565     
Gender (Female / Male) 1.11 (0.57-2.18) 0.753     
Operative Approach (TTO / THO) 0.60 (0.34-1.04) 0.069   0.622  
CRP (Normal / High) 1.92 (1.12-3.30) 0.017   0.513  
V ̇O2Peak  (Normal / Low) 1.54 (0.95-2.48) 0.079   0.720  
Neoadjuvant therapy (No / Yes) 1.00 (0.98-1.02) 0.936 
  
Pathological TNM stage (0 / 1 / 2 / 3 / 4) 2.99 (1.99-4.48) <0.001 2.20 (1.37-3.55) 0.001  
Differentiation (Well-moderate / Poor) 2.92 (1.75-4.88) <0.001 2.20 (1.21-4.00) 0.010 
CRM Margin (Negative / Positive) 1.75 (1.44-2.13) <0.001 2.33 (1.14-4.77) 0.021 
Lymph Node Yield (<15 / ≥ 15) 1.62 (0.93–2.81) 0.088  0.746 
Major Morbidity (No / Yes) 2.09 (1.22-3.59) 0.007 4.56 (2.35-8.84) <0.001 
Combined Inflammatory and Physiology Score (0 / 1 / 2) 1.68 (1.17-2.42) 0.005  0.934 
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Table 4. Factors associated with Disease-Free Survival 
 
  Univariable 
HR (95% CI) 
  
p-value 
Multivariable 
HR (95% CI) 
  
p-value 
Age (<65 / 66-75 / >75 yr) 1.09 (0.68-1.76) 0.722     
Gender (Female / Male) 2.06 (0.63-6.73) 0.230     
Operative Approach (TTO / THO) 1.17 (0.58-2.35) 0.657   
 
CRP (Normal / High) 1.03 (0.40-2.65) 0.949   
 
V ̇O2Peak  (Normal / Low) 1.21 (0.63-2.32) 0.571   
 
Neoadjuvant therapy (No / Yes) 0.98 (0.91-1.05) 0.544 
  
Pathological TNM stage (0 / 1 / 2 / 3 / 4) 2.33 (1.51-3.57) <0.001  2.08 (1.24-3.50) 0.005  
Differentiation (Well-moderate / Poor) 3.21 (1.60-6.45) 0.001   0.055 
CRM Margin (Negative / Positive) 2.06 (1.07-3.98) 0.031 
 
0.849 
Lymph Node Yield (<15 / ≥ 15) 1.31 (0.67–2.55) 0.428   
Major Morbidity (No / Yes) 1.57 (0.71-3.45) 0.262   
Combined Inflammatory and Physiology Score (0 / 1 / 2) 1.16 (0.67-2.01) 0.603   
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Figure 1. Predictive value of (A) CRP, (B) V ̇O2Peak, and major morbidity 
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Figure 2. Cumulative OS related to (A) Combined Physiological and 
Inflammatory Score and (B) Major Morbidity  
 
 
 . CC-BY-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted April 19, 2020. .https://doi.org/10.1101/2020.04.16.20067769doi: medRxiv preprint 
